
Please try another search
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Jay M. Short | 63 | 2007 | Co-Founder, CEO & Chairman |
Lawrence Steinman | 75 | 2016 | Independent Director |
Padmanee Sharma | - | 2017 | Advisor |
Scott Andrew Smith | 61 | 2018 | Director |
James Patrick Allison | - | 2017 | Advisor |
Sylvia S. McBrinn | - | 2021 | Independent Director |
Mary Ann Gray | 70 | 2020 | Independent Director |
Lawrence Fong | - | 2018 | Scientific Advisor |
Edward L. Williams | 68 | 2021 | Independent Director |
Susan Moran | 54 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review